Paper · 35636624
Deubiquitinase USP8 increases ID1 stability and promotes esophageal squamous cell carcinoma tumorigenesis.
Li L and 7 others. Cancer Lett, 2022. Cited by 10 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Deubiquitinase USP8 increases ID1 stability and promotes esophageal squamous cell carcinoma tumorigenesis. Papers, record 35636624. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35636624
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Deubiquitinase USP8 increases ID1 stability and promotes esophageal squamous cell carcinoma tumorigenesis.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Endopeptidases | Major topic |
| Endosomal Sorting Complexes Required for Transport | Major topic |
| Esophageal Neoplasms | Major topic |
| Esophageal Squamous Cell Carcinoma | Major topic |
| Inhibitor of Differentiation Protein 1 | Major topic |
| Ubiquitin Thiolesterase | Major topic |
| Carcinogenesis | |
| Cell Line, Tumor | |
| Cell Movement | |
| Cell Proliferation | |
| Cell Transformation, Neoplastic | |
| Deubiquitinating Enzymes | |
| Humans | |
| Ubiquitination |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,558,564 | Inhibitor of DNA binding 1 in lung cancer and the tumor microenvironment: a testable hypothesis for malignant pleural effusion formation. | Front Immunol | 2026 | https://conductscience.org/library/papers/42558564 | PubMed |
| 41,331,709 | Deciphering USP8's pivotal role in cancer: mechanisms, clinical insights and contrasts with its function in pituitary adenomas. | J Transl Med | 2025 | https://conductscience.org/library/papers/41331709 | PubMed |
| 40,652,518 | TRIM21-Mediated K11-Linked Ubiquitination of ID1 Suppresses Tumorigenesis and Promotes Cuproptosis in Esophageal Squamous Cell Carcinoma. | Adv Sci (Weinh) | 2025 | https://conductscience.org/library/papers/40652518 | PubMed |
| 39,852,234 | High FGF18 expression levels predict poor prognosis in endometrial carcinoma patients and promote tumor growth and metastasis. | J Int Med Res | 2025 | https://conductscience.org/library/papers/39852234 | PubMed |
| 39,702,934 | USP8-Dependent Family Tyrosine Kinase Promotes the Malignant Progression of Esophageal Squamous Cell Carcinoma by Upregulating Protein Tyrosine Kinase 2 Expression. | Thorac Cancer | 2025 | https://conductscience.org/library/papers/39702934 | PubMed |
| 38,697,989 | Multimodal analysis of cfDNA methylomes for early detecting esophageal squamous cell carcinoma and precancerous lesions. | Nat Commun | 2024 | https://conductscience.org/library/papers/38697989 | PubMed |
| 37,794,178 | The role of TXNIP in cancer: a fine balance between redox, metabolic, and immunological tumor control. | Br J Cancer | 2023 | https://conductscience.org/library/papers/37794178 | PubMed |
| 37,679,322 | USP32 deubiquitinase: cellular functions, regulatory mechanisms, and potential as a cancer therapy target. | Cell Death Discov | 2023 | https://conductscience.org/library/papers/37679322 | PubMed |
Genes8
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ID1 | 3,397 | PubTator's text mining | https://conductscience.org/library/genes/3397 | NCBI Gene |
| PSMD14 | 10,213 | PubTator's text mining | https://conductscience.org/library/genes/10213 | NCBI Gene |
| TXNIP | 10,628 | PubTator's text mining | https://conductscience.org/library/genes/10628 | NCBI Gene |
| UCHL1 | 7,345 | PubTator's text mining | https://conductscience.org/library/genes/7345 | NCBI Gene |
| USP10 | 9,100 | PubTator's text mining | https://conductscience.org/library/genes/9100 | NCBI Gene |
| USP39 | 10,713 | PubTator's text mining | https://conductscience.org/library/genes/10713 | NCBI Gene |
| USP7 | 7,874 | PubTator's text mining | https://conductscience.org/library/genes/7874 | NCBI Gene |
| USP8 | 9,101 | PubTator's text mining | https://conductscience.org/library/genes/9101 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35636624
GET https://conductscience.org/api/papers/v1/35636624/authors